Any feedback?
Information on EC 2.4.1.65 - 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferase and Organism(s) Homo sapiens and UniProt Accession Q11130
for references in articles please use BRENDA:EC2.4.1.65Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.4.1.65 3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferaseIUBMB Comments
This enzyme is the product of the Lewis blood group gene. Normally acts on a glycoconjugate where R (see reaction) is a glycoprotein or glycolipid. Although it is a 4-fucosyltransferase, it has a persistent 3-fucosyltransferase activity towards the glucose residue in free lactose. This enzyme fucosylates on O-4 of an N-acetylglucosamine that carries a galactosyl group on O-3, unlike EC 2.4.1.152, 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase, which fucosylates on O-3 of an N-acetylglucosamine that carries a galactosyl group on O-4. Enzymes catalysing the 4-alpha-fucosylation of the GlcNAc in beta-D-Gal-(1->3)-beta-GlcNAc sequences (with some activity also as 3-alpha-fucosyltransferases) are present in plants, where the function in vivo is the modification of N-glycans. In addition, the fucTa gene of Helicobacter strain UA948 encodes a fucosyltransferase with both 3-alpha- and 4-alpha-fucosyltransferase activities.
Specify your search results
Word Map
- 2.4.1.65
-
fucosylation
-
sialylated
-
fucts
- selectins
-
e-selectin
- gdp-fucose
- n-acetyllactosamine
-
sialyl-lewis
-
lewisa
- synthesis
- lacto-n-neotetraose
- lacto-n-tetraose
- fuct-iv
-
alpha1,3fucosyltransferase
- molecular biology
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
The enzyme appears in selected viruses and cellular organisms
Reaction Schemes
Synonyms
fuc-t, fuc-tiii, alpha-1,3-fucosyltransferase, fucosyltransferase iv, fuct-iii, fuct-vi, fuct iii, fuct v, fucosyltransferase vi, ft-iv, 
more
topSYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
(Lea)-dependent alpha-3/4-fucosyltransferase
-
-
-
-
alpha(1,3/1,4) fucosyltransferase III
-
-
-
-
alpha(1,3/4) fucosyltransferase
-
-
-
-
alpha-(1->4)-L-fucosyltransferase
-
-
-
-
alpha-4-L-fucosyltransferase
-
-
-
-
alpha4-fucosyltransferase
-
-
-
-
alpha4-FucT
-
-
-
-
beta-acetylglucosaminylsaccharide fucosyltransferase
-
-
-
-
blood group Lewis alpha-4-fucosyltransferase
-
-
-
-
blood-group substance Lea-dependent fucosyltransferase
-
-
-
-
Fuc-TIII
-
-
-
-
fucosyltransferase, guanosine diphosphofucose-beta-acetylglucosaminylsaccharide 4-alpha-L-
-
-
-
-
fucosyltransferase, guanosine diphosphofucose-glycoprotein 4-alpha-
-
-
-
-
FucT VI
FucT-II
-
-
-
-
FucT-III
FucT-V
FucT-VI
FucTIII
-
-
-
-
FUT10
FUT11
FUT3
FUT5
FUT6
GDP-Fuc: beta-D-Galp-(1-3/4)-beta-D-GlcpNAc-(1-4'/3')-alpha-fucosyltransferase
-
-
guanosine diphosphofucose-glycoprotein 4-alpha-L-fucosyltransferase
-
-
-
-
Lewis alpha-3/4-fucosyltransferase
Lewis alpha1-3/4 fucosyltransferase
-
-
-
-
Lewis blood group alpha1-3/4 fucosyltransferase
-
-
-
-
Lewis(Le) blood group gene-dependent alpha-3/4-L-fucosyltransferase
-
-
-
-
SFT3
FUT3
-
-
-
-
Lewis alpha-3/4-fucosyltransferase
-
-
-
-
SFT3
-
-
-
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
hexosyl group transfer
hexosyl group transfer
-
-
-
-
PATHWAY SOURCE
PATHWAYS
KEGG
-
-, -, -
SYSTEMATIC NAME
IUBMB Comments
GDP-beta-L-fucose:beta-D-galactosyl-(1->3)-N-acetyl-D-glucosaminyl-R 4I-alpha-L-fucosyltransferase
This enzyme is the product of the Lewis blood group gene. Normally acts on a glycoconjugate where R (see reaction) is a glycoprotein or glycolipid. Although it is a 4-fucosyltransferase, it has a persistent 3-fucosyltransferase activity towards the glucose residue in free lactose. This enzyme fucosylates on O-4 of an N-acetylglucosamine that carries a galactosyl group on O-3, unlike EC 2.4.1.152, 4-galactosyl-N-acetylglucosaminide 3-alpha-L-fucosyltransferase, which fucosylates on O-3 of an N-acetylglucosamine that carries a galactosyl group on O-4. Enzymes catalysing the 4-alpha-fucosylation of the GlcNAc in beta-D-Gal-(1->3)-beta-GlcNAc sequences (with some activity also as 3-alpha-fucosyltransferases) are present in plants, where the function in vivo is the modification of N-glycans. In addition, the fucTa gene of Helicobacter strain UA948 encodes a fucosyltransferase with both 3-alpha- and 4-alpha-fucosyltransferase activities.
CAS REGISTRY NUMBER
COMMENTARY
37277-69-3
-
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
Fucalpha(1-2)Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Fucalpha(1-2)Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Fucalpha(1-2)Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Fucalpha(1-2)Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
GDP-beta-L-fucose + beta-D-galactosyl-(1->3)-N-acetyl-D-glucosaminyl-R
GDP + beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-R
-
isoform Fut3 predominantly exhibits alpha1-4 fucosyltransferase activity
-
-
?
GDP-beta-L-fucose + beta-D-Galp-(1,3)-beta-D-GlcNAcp-O-(CH2)6-NH-dansyl
GDP + beta-D-Galp-(1,3)[alpha-L-Fuc-(1,4)]-beta-D-GlcNAcp-O-(CH2)6-NH-dansyl
-
-
-
-
?
GDP-beta-L-fucose + Fucalpha(1->2)Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Fucalpha1,2Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha(2->3)Galbeta(1->3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha(2->3)Galbeta(1->4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
?
-
-
-
-
?
GDP-beta-L-fucose + NeuAcalpha2-3Galbeta1-4Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
?
-
the enzyme catalyzes the fucose transfer from GDP-fucose to GlcNAc residues of the sialylated polylactosamine acceptor leading to two isomeric monofucosyl antigens, VIM2 and sialyl-Lex
-
-
?
GDP-beta-L-fucose + NeuAcalpha2-3Galbeta1-4Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
GDP + NeuAcalpha2-3Galbeta1-4[Fucalpha1-3]Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
-
the enzyme catalyzes the fucose transfer from GDP-fucose to GlcNAc residues of the sialylated polylactosamine acceptor leading to two isomeric monofucosyl antigens, VIM2 and sialyl-Lex
i.e. sialyl-Lex, main product of FucT-VI, i.e. VIM2, main product of FucT-V
-
?
GDP-beta-L-fucose labelled with ATTO 550 + N-acetyllactosamine labelled with ATTO 647N
?
-
-
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,4GlcNAc
GDP + 2-O-MeGal-beta-1,4(Fuc-alpha-1,3)GlcNAc
100% activity
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-sp-biotin
type 1 reaction
-
-
?
GDP-fucose + Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
GDP + Fuc-alpha-1,2Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc-sp-biotin
type 2 reaction
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc-beta-1,3Gal-beta-1,4Glc
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-beta-1,3Gal-beta-1,4Glc
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAc-O-(CH2)3NHCO(CH2)5NH-biotin
GDP + Gal-beta-1,3(Fuc-alpha-1,4)GlcNAc-O-(CH2)3NHCO(CH2)5NH-biotin
-
-
-
-
?
GDP-fucose + Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
GDP + Gal-beta-1,3[alpha-L-fucosyl-(1,4)]GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
-
-
-
?
GDP-fucose + Gal-beta-1,4GlcNAc
GDP + Gal-beta-1,4(Fuc-alpha-1,3)GlcNAc + Gal-beta-1,4(Fuc-alpha-1,2)GlcNAc
-
enzyme activity is divided into 66% alpha-1,3FucT and 34% alpha-1,2FucT
-
-
?
GDP-fucose + Gal-beta-1,4GlcNAc-beta-1-R
GDP + Gal-beta-1,4(fuc-alpha-1,3)GlcNAc-beta-1-R
-
-
-
-
?
GDP-fucose + GalNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GalNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
?
acivity not determined
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
GDP + ?
63.8% acivity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
?
acivity not determined
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc-beta-1,4GlcNAc
GDP + ?
61.5% acivity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GlcNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
GDP-L-fucose + (Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
GDP + Fucalpha(1-3)(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
-
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
GDP-L-fucose + 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn
GDP + 2-O-MeGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
-
-
-
?
GDP-L-fucose + 3-O-MeGalbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + 3-O-MeGalbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
16.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 17.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,3)GlcNAcbeta(1,3)Galbeta-O-Al
GDP + 3-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta-O-Al
-
64.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 82.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
GDP + 3-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Al
-
64.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 62.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 3-O-sulfoGalbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + 3-O-sulfoGalbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
10.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 14.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + 6-O-sulfoGalbeta(1,3)GlcNAcbeta-O-Al
GDP + 6-O-sulfoGalbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Al
-
3.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + alpha(2,3)-sialyllactosamine
GDP + ?
-
56% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
GDP + ?
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + ?
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)5-NH-biotin
-
193% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc-R
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))Glc
-
34.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 38.7% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
3% of the activity with with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin, enzyme expressed in Sf9 cells
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc-(CH2)5-NH-biotin
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)5-NH-biotin
-
9.3% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAc-R
GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Galalpha(1,3)Galbeta(1,3)GlcNAcbeta-O-Naph
GDP + Galalpha(1,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Naph
-
42.6 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 46.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,3)(6-O-sulfo)GlcNAcbeta(1,3)Galbeta-O-Al
GDP + ?
-
15.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 19.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc-R
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc-R
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
20% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAcbeta-O-Bn
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
79.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 83.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)-(5-thioGlc)
GDP + ?
-
51% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
2% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin, enzyme expressed in Sf9 cells
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
33% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(3-O-MeGalbeta(1,3))GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(3-O-MeGalbeta(1,3))GalNAcalpha-O-Bn
-
2.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(3-O-sulfoGalbeta(1,3))-GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(3-O-sulfoGalbeta(1,3))-GalNAcalpha-O-Bn
-
1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-O-Bn
-
2.3% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 1.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta-O-Bn
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta-O-Bn
-
3.1% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 2.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbetaOallyl
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl
-
64% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)Glucal
GDP + Galbeta(1,4)(Fucalpha(1,3))Glucal
-
10% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1-3)GlcNAcbeta-O-Me
GDP + Fucalpha(1-3)Galbeta(1-3)GlcNAcbeta-O-Me
-
-
-
-
?
GDP-L-fucose + GalNAcbeta(1,3)(6-O-sulfo)GlcNAcbeta-O-Me
GDP + ?
-
6.2 of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 8.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + GalNAcbeta1-4GlcNAc-octyl
GDP + ?
-
shows the highest catalytic activity as an acceptor substrate
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
GDP + N-[(1R,3R,5R,6S,7S,8R,13R,15R,16R,17S)-6,17-dihydroxy-5-hydroxymethyl-15-methoxy-7-((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl]-acetamide
-
low activity with FucT IV and FucT VI
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
GDP + N-[(1R,3R,5R,6S,7S,8R,13R,15R,16R,17S)-6,17-dihydroxy-5-hydroxymethyl-15-methoxy-7-((2R,3R,4S,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydro-pyran-2-yloxy)-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl]-acetamide
-
-
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
GDP + ?
-
-
-
-
?
GDP-L-fucose + N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
GDP + ?
-
-
-
-
?
GDP-L-fucose + N-acetyllactosamine
GDP + alpha-1,3-L-fucosyl-N-acetyllactosamine
-
-
-
-
?
GDP-L-fucose + NeuAc(2,3)Galbeta(1,4)Glucal
GDP + NeuAc(2,3)Galbeta(1,4)(Fucalpha(1,3))Glucal
-
330% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAc(2,6)Galbeta(1,4)GlcNAc
GDP + NeuAc(2,6)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
13% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAc-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAc-(CH2)5-NH-biotin
-
57% of the activity with Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,3)GlcNAcbeta-O-Bn
GDP + NeuAcalpha(2,3)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta-O-Bn
-
55.8% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 64.4% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAc
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
620% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
-
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
24.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 12.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta-O-Bn
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta-O-Bn
-
6.2% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 7.6% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbetaOallyl
GDP + NeuAcalpha(2,3)Galbeta(1,4)(Fucalpha(1,3))GlcNAcbetaOallyl
-
380% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)AspNHCO-biotin + GDP
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-3)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
NeuAcalpha(2-3)Galbeta(1-3)[Fucalpha(1-4)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
NeuAcalpha(2-3)Galbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
NeuAcalpha(2-3)Galbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc
GDP + 2-O-MeGal-beta-1,3(Fuc-alpha-1,4)GlcNAc
17.6% activity
-
-
?
GDP-fucose + 2-O-MeGal-beta-1,3GlcNAc
GDP + 2-O-MeGal-beta-1,3(Fuc-alpha-1,4)GlcNAc
19.4% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein
GDP + ?
42.9% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo agalacto glycoprotein
GDP + ?
5.2% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo glycoprotein
GDP + ?
36.9% activity
-
-
?
GDP-fucose + Fetuin triantennary asialo glycoprotein
GDP + ?
73.8% activity
-
-
?
GDP-fucose + GalNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GalNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
91.9% activity
-
-
?
GDP-fucose + GalNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GalNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
95.0% activity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GlcNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
11.3% activity
-
-
?
GDP-fucose + GlcNAc-beta-1,4GlcNAc-beta-O-Bn
GDP + GlcNAc-beta-1,4(Fuc-alpha-1,3)GlcNAc-beta-O-Bn
89.1% activity
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme catalyzes the synthesis of fucosylated Lewis motifs that are associated with cell-adhesion events and are differentially expressed during cell differentiation
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
-
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-1,4-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme has a clear preference for the Galbeta3GlcNAc motif in oligosaccharides conjugated with the hydrophobic tail (CH2)3-NHCO-(CH2)5-NH-biotin
-
-
?
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
-
254% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + 2'-fucosyllactose
GDP + ?
-
11% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + asialofetuin
GDP + ?
-
the acceptor oligosaccharide in bovine asialofetuin is the man3 branched triantennary isomer with one Galbeta(1,3)GlcNAc
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
activity of the wild-type enzyme is about 3% of the activity with Fucalpha(1,2)Galbeta(1,4)GlcNAc. The mutation W111R shows higher activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc than for Fucalpha(1,2)Galbeta(1,4)GlcNAc. The addition mutation in W11R/D112E increases activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc compared to mutant W111R
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
GDP + Fucalpha(1,2)Galbeta(1,3)(Fucalpha(1,4))GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
i.e. lacto-N-fucopentaose I
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
-
-
-
?
GDP-L-fucose + Fucalpha(1,2)Galbeta(1,4)GlcNAc
GDP + Fucalpha(1,2)Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
mutant enzyme D336A shows 40fold reduction in activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
-
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
130% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
29% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
420% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,3)GlcNAc
GDP + Galbeta(1,3)(Fucalpha(1,4))GlcNAc
-
45.0% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 51% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
145% of the activity with Galbeta(1,4)GlcNAc
-
-
?
GDP-L-fucose + Galbeta(1,4)Glc
GDP + Galbeta(1,4)(Fucalpha(1,3))Glc
-
i.e. lactose, 2% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
i.e. N-acetyllactosamine
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
3.9% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTA. 3.5% of the activity with 2-O-MeGalbeta(1,3)GlcNAcbeta-O-Bn, enzyme form FTB
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAc
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAc
-
43% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
-
-
-
-
?
GDP-L-fucose + Galbeta(1,4)GlcNAcbeta(1,2)Man
GDP + Galbeta(1,4)(Fucalpha(1,3))GlcNAcbeta(1,2)Man
-
28% of the activity with Fucalpha(1,2)Galbeta(1,3)GlcNAcbeta(1,3)Galbeta(1,4)Glc
-
-
?
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
-
on the cell surface of hepatocarcinoma cells H7721
-
-
?
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
-
the enzyme, especially subtype FucT VI, is responsible for alpha-1,3-fucosylation in the synthesis of Lewis antigens Lex, SLex, and SDLex on the cell surface consist of sialylated or nonsialylated N-acetyllactosamine located on the outer chains of the glycan moieties of glycolipids or the O-linked glycans of glycoproteins, the isozymes prefer sialylated, alphaFucT III, V, VI, and VII, or nonsialylated, alphaFucT IV and IX, N-acetyllactosamine
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
-
-
-
?
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP-L-fucose
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)[Fucalpha(1-3)]GlcNAcbeta(1-)(CH2)3-NHCO-(CH2)5-NH-biotin + GDP
FUT10 activity toward the acceptor 0989-BM is increased by about 50% compared with those observed using BGA-biotin
-
-
?
additional information
?
-
-
11 nonidentical amino acids, found within a hypervariable peptide segment positioned at the NH2 terminus determins whether or not a alpha(1,3)-fucosyltransferase can utilize type I acceptor substrates to form Lewis a and sialyl Lewis a moieties
-
-
?
additional information
?
-
-
activity with type 2 substrates is 1% or less than the activity with type 1 substrates
-
-
?
additional information
?
-
-
high substrate affinity for clustered units of 3-sialyl Galbeta(1,3)GlcNAcbeta in asparagine linked carbohydrate as well as for mucin core 2 structure containing 3-sialyl Galbeta1,4GlcNAcbeta-unit, in addition of alpha(1,2)-L-fucosylating activity
-
-
?
additional information
?
-
-
the enzyme transferrs fucose to the O-4-position of GlcNAc in small oligosaccharides, glycolipids, glycopeptides and glycoproteins containing the type I Galbeta(1,3)GlcNAc motif
-
-
?
additional information
?
-
the enzyme is involved in the biosynthesis of the E-selectin ligand, sialyl-Lewis X. Catalyzes the transfer of fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates
-
-
?
additional information
?
-
-
the enzyme is involved in the biosynthesis of the E-selectin ligand, sialyl-Lewis X. Catalyzes the transfer of fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates
-
-
?
additional information
?
-
-
the enzyme is involved in the biosynthesis of the sialyl Lewis x, i.e. Lex, epitope on leukocytes, which has been identified as an important component of leukocyte ligands for E- and P-selectin
-
-
?
additional information
?
-
-
no activity with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-beta-1,3Gal-beta-1,4Glc, Fuc-alpha-1,2Gal-beta-1,4Glc, and NeuAc-alpha-2,3-Gal-beta-1,4GlcNAc
-
-
?
additional information
?
-
-
substrate specificity of FucT IV and FucT VI with N-acetyllactosamine derivatives, determination of the required conformational properties of oligosaccharide acceptors
-
-
?
additional information
?
-
-
the strong correlation between the promoter activity of the FUT III gene and the high expression of sialyl Le(a) observed in different colon carcinoma cell lines seems to conform the important regulatory role of FUT3 in the synthesis of sialyl Le(a)
-
-
?
additional information
?
-
-
FucT-III and FucT-V catalyze fucose transfer to Galbeta1-3GlcNAc chain acceptors in an alpha1,4-linkage, these two enzymes have distinct site-specific fucosylation properties, site-specific fucosylation is defined within a 40-amino acid segment containing 8 amino acid differences between the two enzymes, FucT-VI has about 12fold higher activity compared with FucT-V with the Trp124/Arg110 site in the enzymes being responsible primarily for this activity difference, substrate specificities of wild-type and mutant enzymes, overview
-
-
?
additional information
?
-
-
FucT-III catalyzes the transfer of fucose onto position-4 or position-3 of the N-acetylglucosamine unit of disaccharides beta-D-Galp-(1,3)-beta-D-GlcpNAc or beta-D-Galp-(1,4)-beta-D-GlcpNAc, respectively. FucT-III is an inverting enzyme
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galb1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galb1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galbeta1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
FucT3 and FucT5 possess alpha1,4FucT activity to fucosylate type 1 chains, but FucT3, as well as FucT6, account also for alpha3-fucosylation of type 2 chain in Colo205. FucT3 alone is responsible for synthesizing Lea and (sialyl) Lewis a, (sialyl)Galbeta1-(Fucalpha1-4)3GlcNAcbeta-(s)Lea in Colo205
-
-
?
additional information
?
-
-
FUT6 can synthesize sialyl Lewis x in KATO III cells whereas FUT5 is most likely responsible for the synthesis of this epitope in HT29 and MKN45 cells. FUT3 and to a lower extent FUT5 have the capability to synthesize sialyl Lewis a
-
-
?
additional information
?
-
-
the enzyme transfers fucose from the GDP-fucose donor onto different glycoconjugate acceptors, such as, glycoproteins, glycolipids and oligosaccharides. Isoforms FUT3 to FUT7 and FUT9 to FUT11 belong to the group of alpha1,3/4-fucosyltransferases. FUT3 predominantly exhibits alpha1,4-fucosyltransferase activity synthesizing Lewis a, NeuAcalpha2,3Galbeta(1->3)[Fucalpha(1->4)]GlcNAc-R and Lewis b, and a minor alpha1,3-FUT activity, synthesizing Lewis x, sialyl Lewis x and Lewis y. FUT5 and FUT6 synthesize Lewis x and NeuAcalpha2,3Galbeta(1->4)[Fucalpha(1->3)]GlcNAc-R. FUT7 is an alpha1,3-FUT that synthesizes only sialyl Lewis x. FUT4 and FUT9 produce Lewis x and Lewis y. FUT10 and FUt11 exhibit alpha1,3-fucosyltransferase activity
-
-
?
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
GDP-beta-L-fucose + beta-D-galactosyl-(1->3)-N-acetyl-D-glucosaminyl-R
GDP + beta-D-galactosyl-(1->3)-[alpha-L-fucosyl-(1->4)]-N-acetyl-beta-D-glucosaminyl-R
-
isoform Fut3 predominantly exhibits alpha1-4 fucosyltransferase activity
-
-
?
GDP-beta-L-fucose + NeuAcalpha2-3Galbeta1-4Glc-NAcbeta1-3Galbeta1-4GlcNAcbeta1-3Galbeta1-4Glcbeta1-ceramide
?
-
the enzyme catalyzes the fucose transfer from GDP-fucose to GlcNAc residues of the sialylated polylactosamine acceptor leading to two isomeric monofucosyl antigens, VIM2 and sialyl-Lex
-
-
?
GDP-fucose + Gal-beta-1,4GlcNAc-beta-1-R
GDP + Gal-beta-1,4(fuc-alpha-1,3)GlcNAc-beta-1-R
-
-
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
GDP-L-fucose + Lewis antigen
GDP + fucosylated Lewis antigen
-
on the cell surface of hepatocarcinoma cells H7721
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme catalyzes the synthesis of fucosylated Lewis motifs that are associated with cell-adhesion events and are differentially expressed during cell differentiation
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
-
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
GDP-L-fucose + 1,3-beta-D-galactosyl-N-acetyl-D-glucosaminyl-R
GDP + 1,3-beta-D-galactosyl-(alpha-(1,4)-L-fucosyl)-N-acetyl-D-glucosaminyl-R
the enzyme may catalyze alpha1-3 and alpha-1,4 glycosidic linkages involved in the expression of VIM-2, Lewis A, Lewis B, sialyl Lewis X and Lewis X/SSEA-1 antigens. May be involved in blood group Lewis determination. Lewis-positive individuals have an active enzyme while Lewis-negative individuals have an inactive enzyme
-
-
?
additional information
?
-
the enzyme is involved in the biosynthesis of the E-selectin ligand, sialyl-Lewis X. Catalyzes the transfer of fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates
-
-
?
additional information
?
-
-
the enzyme is involved in the biosynthesis of the E-selectin ligand, sialyl-Lewis X. Catalyzes the transfer of fucose from GDP-beta-fucose to alpha-2,3 sialylated substrates
-
-
?
additional information
?
-
-
the enzyme is involved in the biosynthesis of the sialyl Lewis x, i.e. Lex, epitope on leukocytes, which has been identified as an important component of leukocyte ligands for E- and P-selectin
-
-
?
additional information
?
-
-
the strong correlation between the promoter activity of the FUT III gene and the high expression of sialyl Le(a) observed in different colon carcinoma cell lines seems to conform the important regulatory role of FUT3 in the synthesis of sialyl Le(a)
-
-
?
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Zn2+
can replace Mn2+ for activation, but shows only half the maximal activity, optimum concentration is 10-15 mM
Ca2+
Co2+
Mg2+
Mn2+
Zn2+
additional information
Mn2+
-
binds the enzyme and increases affinity for the acceptor. One possible functional role of manganese in catalysis can be as an electrophilic catalyst, co-ordinating the negative charges of the phosphate groups of the GDP-Fuc donor and promoting Fuc transfer. A low pH values such role would be played by the proton. Mn2+ leads to 2.7fold activation of SFT3
additional information
-
the enzyme retains approximately 35% of its maximal activity in the absence of metal ions
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
9-(5'-O-[(alpha,beta-L-fucopyranosyl)oxycarbonylaminosulfonyl]-beta-D-ribofuranosyl)-guanine
-
poor competitive inhibition
[1-(beta-D-fucopyranosyl)-1H-1,2,3-triazole-4-yl]methylguanosine diphosphate
-
about 70% inhibition at 0.4 mM
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazole-4-yl] methylguanosine diphosphate
-
about 73% inhibition at 0.4 mM
[1-(beta-D-lactosyl)-1H-1,2,3-triazole-4-yl]methylguanosine diphosphate
-
about 45% inhibition at 0.4 mM
[1-(beta-L-fucopyranosyl)-1H-1,2,3-triazole-4-yl]methylguanosine diphosphate
-
about 60% inhibition at 0.4 mM
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.075 - 1.3
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
0.15 - 0.154
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
3 - 25
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
1.1 - 11
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
0.61 - 16
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
0.4 - 5
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
0.12
(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
pH 6.5, 37°C, recombinant FucT VI
2.7
(Gal-3-O-Me)beta(1-3)(GlcNAc-6-O-Me)beta-O-Me
-
pH 6.5, 37°C, recombinant FucT IV
0.075
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
-
pH 6.5, 37°C, recombinant FucT VI
1.3
Formic acid (2R,3R,4S,5R,6R)-2-((2R,3R,4R,5R,6R)-3-acetylamino-5-hydroxy-2-methoxy-6-methylaminomethyl-tetrahydro-pyran-4-yloxy)-4,5-dihydroxy-6-hydroxymethyl-tetrahydro-pyran-3-yl ester
-
pH 6.5, 37°C, recombinant FucT IV
0.3
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111F
0.3
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111Y
2.5
Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
mutant W111A
0.1
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
mutant W124R
1.3
Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
mutant W124Y
3.8
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
fucosyltransferase III mutant enzyme D336A
0.7
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 7.0 and presence of Mn2+
0.9
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 4.7 and absence of Mn2+
1.5
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 4.7 and presence of Mn2+
3.3
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 7.0 and absence of Mn2+
0.76
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
enzyme expressed n Sf9 cells
0.87
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
enzyme expressed in Trichoplusia ni
0.03
GDP-fucose
mutant W124R, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.034
GDP-fucose
mutant W111Y, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.035
GDP-fucose
mutant W124Y, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.035
GDP-fucose
wildtype, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.037
GDP-fucose
mutant W111F, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.038
GDP-fucose
wildtype, with Fuc-alpha-1,2Gal-beta-1,4GlcNAc-sp-biotin
0.046
GDP-fucose
mutant W111A, with Fuc-alpha-1,2Gal-beta-1,3GlcNAc-sp-biotin
0.15
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
FUT10-479
0.154
GlcNAcbeta(1-2)Manalpha(1-6)[GlcNAcbeta(1-2)Manalpha(1-3)]Manbeta(1-4)GlcNAcbeta(1-4)GlcNAcbeta(1-)AspNHCO-biotin
FUT10-391
3
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
25
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.0 3,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
1.1
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
11
N-((1R,3R,5R,6R,7S,8R,13R,15R,16R,17S)-6,7,17-Trihydroxy-5-hydroxymethyl-15-methoxy-2,4,9,11,14-pentaoxa-tricyclo[11.3.1.03,8]heptadec-16-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.61
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
16
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18R)-6,7,18-trihydroxy-5-hydroxymethyl-16-methoxy-11-oxo-2,4,9,15-tetraoxa-12-aza-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.4
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT VI
5
N-((1R,3R,5R,6R,7S,8R,14R,16R,17R,18S)-6,7,18-Trihydroxy-5-hydroxymethyl-16-methoxy-2,4,9,12,15-pentaoxa-tricyclo[12.3.1.03,8]octadec-17-yl)-acetamide
-
pH 6.5, 37°C, recombinant FucT IV
0.77
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
enzyme form FTB
3.3
NeuAcalpha(2,3)Galbeta(1,4)GlcNAcbeta(1,6)(Galbeta(1,3))GalNAcalpha-OMe
-
enzyme form FTB
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
3.02
Fucalpha(1,2)Galbeta(1,3)GlcNAc
-
fucosyltransferase III mutant enzyme D336A
0.1
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 7.0 and absence of Mn2+
0.2
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 4.7 and presence of Mn2+
0.2
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 7.0 and presence of Mn2+
0.3
Gal-beta-1,3GlcNAcO(CH2)3NHCO(CH2)5NH-biotin
-
at pH 4.7 and absence of Mn2+
0.009
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
enzyme expressed in Sf9 cells
0.4
Galbeta(1,3)GlcNAc-(CH2)3-NHCO-(CH2)5-NH-biotin
-
enzyme expressed in Trichoplusia ni
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.115
2,5-dihydroxybenzoic acid
presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose
0.137
3,4-dihydroxybenzoic acid
presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose
0.0012
ellagic acid
presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose
0.008
methyl gallate
presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose
0.045
propyl gallate
presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose
0.19
[1-(beta-D-fucopyranosyl)-1H-1,2,3-triazole-4-yl]methylguanosine diphosphate
-
at pH 4.5 and 37°C
0.186
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazole-4-yl] methylguanosine diphosphate
-
at pH 4.5 and 37°C
0.137
[1-(beta-L-fucopyranosyl)-1H-1,2,3-triazole-4-yl]methylguanosine diphosphate
-
at pH 4.5 and 37°C
additional information
additional information
2,3-dihydroxybenzoic acid: above 0.200, presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, 2,4-dihydroxybenzoic acid: above 0.200, presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, 3,5-dimethoxy 4-hydroxybenzoic acid: above 0.200, presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, 3,4-dimethoxybenzoic acid: above 0.200, presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, 3,4,5-trimethoxybenzoic acid: above 0.200, presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose
-
0.0007
(-)-epigallocatechin-3-gallate
presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose
0.0022
(-)-epigallocatechin-3-gallate
overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, MnCl2 omitted in the overnight pre-incubation mixture
0.00006
3,4,5-Trihydroxybenzoic acid
presence of MnCl2, overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose
0.0054
3,4,5-Trihydroxybenzoic acid
overnight (15 h) pre-incubation of compound and enzyme before initiation of the reaction with GDP-fucose, MnCl2 omitted in the overnight pre-incubation mixture
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
20
9-(5'-O-[(alpha,beta-L-fucopyranosyl)oxycarbonylaminosulfonyl]-beta-D-ribofuranosyl)-guanine
Homo sapiens
-
-
0.134
[1-(beta-D-fucopyranosyl)-1H-1,2,3-triazole-4-yl]methylguanosine diphosphate
Homo sapiens
-
at pH 4.5 and 37°C
0.247
[1-(beta-D-galactopyranosyl)-1H-1,2,3-triazole-4-yl] methylguanosine diphosphate
Homo sapiens
-
at pH 4.5 and 37°C
0.139
[1-(beta-L-fucopyranosyl)-1H-1,2,3-triazole-4-yl]methylguanosine diphosphate
Homo sapiens
-
at pH 4.5 and 37°C
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
additional information
-
relative activities of wild-type and mutant enzymes, overview
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
6.2 - 8.5
-
pH 6.2: about 70% of maximal activity, pH 8.5: about 90% of maximal activity
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
hepatocarcinoma cell, expression levels of alpha1,3FucT enzyme types in descending order: alphaFucT IV, III, VI, VI, VII, and IX
fetal tissue with weak level, adult tissue with moderate level
additional information
-
low expression of FUT1-6 and FUT9, highest expression of FUT10, FUT11 is absent
-
very low expression of FUT1, FUT3, FUT6 and FUT9, low expression of FUT2, FUT5 and FUT10, higher expression of FUT4, highest expression of FUT11
-
very low expression of FUT1, low expression of FUT2, higher expression of FUT4-6, highest expression of FUT3 and FUT10-11
-
very low expression of FUT1, FUT5 and FUT6, low expression of FUT2, higher expression of FUT9-11, FUT3 is absent, highest expression of FUT4
additional information
-
determination of expression levels in wild-type and R110Q mutant leukocytes
additional information
adult spleen, heart, muscle, liver, and pancreas do not express any of the FUT10 transcripts
additional information
adult spleen, heart, muscle, liver, and pancreas do not express any of the FUT10 transcripts
additional information
-
low expression of FUT1-6 and FUT9 in GP-202 cells, but highest expression of FUT10 and FUT11. Very low expression of FUT1 in IPA-220 cells, low expression of FUT2, higher expression of FUT3-4, FUT6 and FUT10-11, highest expression of FUT5 and FUT9
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
FUT10-419 and FUT10-479, FUT10-479 has the same trans-membrane domain and NH2-terminal endoplasmic reticulum membrane retention signal found in the FUT10-419 splice variant plus a new endoplasmic reticulum membrane retention signal in the COOH terminus
FUT11-476 has no endoplasmic reticulum membrane retention signal, but the FUT11-492 variant has a KKXX-like motif in its COOH terminus that can retain it in the endoplasmic reticulum
FUT10-391 is a soluble protein without a transmembrane domain or endoplasmic reticulum retention signal that transiently localizes to the Golgi and then is routed to the lysosome
-
stable BHK-21 cell lines express the Golgi bound form and two secretory forms of the enzyme
FUT10-419 and FUT10-479 have a type II trans-membrane topology. FUT10-479 has, in addition, a COOH-endoplasmic reticulum membrane retention signal
-
stable BHK-21 cell lines express the Golgi bound form and two secretory forms of the enzyme. 40% of the enzyme activity synthesized by cells transfected with the Golgi form of the enzyme are constitutively secreted into the medium
-
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
-
sperm isoform FUT5 pretreatment or blocking suppresses the protective effect of OE-E6/E7 membrane proteins on sperm motility
metabolism
-
isoform Fut3 expression drives sialyl Lewis A synthesis in V6 variant of CD44-expressing cells
physiological function
physiological function
-
alpha-1,3 fucosyltransferases can enhance metastatic efficiency of prostate cancer by triggering an endothelial selectin-dependent trafficking mechanism. Upregulated FT3, FT6, or FT7 expression induces robust prostate cancer PC-3 cell adhesion to bone marrow endothelium and to inflamed postcapillary venules in an endothelial selectin-dependent manner. FT3, FT6, and FT7 induce sialyl Lewis X expression on metastatic prostate cancer PC-3 cells. Elevated FT7 expression promotes PC-3 cell trafficking to and retention in bone marrow through an endothelial selectin dependent event
physiological function
-
final glycosylation step in sialyl Lewis x and sialyl Lewis a biosynthesis in MKN45 cell line is associated to FUT5, which efficiently fucosylates sialyl Lewis precursors on glycoproteins
physiological function
-
Helicobacter pylori-binding glycosphingolipid isolated from stomach of transgenic alpha-1,3/4-fucosyltransferase-expressing mice as a Fucalpha2Galbeta3 (Fucalpha4)GalNAcbeta4Galbeta4Glcbeta1Cer, i.e. a Leb-like glycosphingolipid on a ganglio core structure. Two other glycosphingolipids are isolated from the mouse stomach epithelium that are found to be nonbinding with regard to Helicobacter pylori, which is a pentaglycosylceramide, GalNAcbeta3Galalpha3(Fucalpha2)Galbeta4Glcbeta1Cer, in which the isoglobo tetrasaccharide is combined with Fucalpha2 to yield an isoglobotetraosylceramide with an internal blood group B determinant. The second one is an elongated fucosyl-gangliotetraosylceramide, GalNAcbeta3(Fucalpha2)Galbeta3GalNAcbeta4Galbeta4Glcbeta1Cer
physiological function
-
role in synthesis of parasitic GalNAc beta1-4(Fuc alpha1-3)GlcNAc beta-R antigen
physiological function
-
fucosyltransferases are responsible for the synthesis of sialyl Lewis a and sialyl Lewis x in gastrointestinal cell lines
physiological function
-
the enzyme plays an important role in hepatocellular carcinoma growth by regulating the PI3K/Akt signaling pathway. Elevating enzyme expression markedly induces intracellular Akt phosphorylation, and suppresses the expression of the cyclin-dependent kinases inhibitor p21. Enzyme overexpression of enhances S-phase cell population, promotes cell growth and colony formation ability
physiological function
-
sperm isoform FUT5 binds to human oviductal epithelial cells
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable).
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
-
disulfide bonds in FucT III occur between Cys residues Cys81 and Cys338 and between Cys91 and Cys341 at the N and C termini of the catalytic domain, bringing theses ends close together in space
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
-
the enzyme is present in an equilibrium of monomer/dimer in the trans-Golgi/trans-Golgi-network of transfected BHK cells
POSTTRANSLATIONAL MODIFICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
glycoprotein
additional information
-
the enzyme expressed in Tn cell line has a lower global charge, possibly due to post-translational modifications, such as phosphorylatopm or sulfation
glycoprotein
-
the two glycosylation sites from SFT3 are occupied by peptide-N-glycanase F, whereas 50% of SFT3 secreted by Tn cells is resistant to deglycosylation by this enzyme
glycoprotein
-
the secretory variant of enzyme contains N-linked endo H sensitive carbohydrate chains at its two glycosylation sites
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
D112E
-
muation decreases activity of the enzyme and does not interfere with H-type 1/H-type 2 acceptors
D125E
-
site-directed mutagenesis of FucT-V, the mutant activity is similar to the wild-type enzyme activity
D336A
-
fucosyltransferase III mutant enzyme shows reduced activity with a variety of acceptors, 40fold reduction in activity for Fucalpha(1,2)Galbeta(1,3)GlcNAc. 4fold reduction affinity for GDP-fucose. The single amino acid site Asp336 of FucT III and Ala349 of FucT V constitutes the only difference in the sequence of FucT III and V over the final 210 COOH-terminal amino acid residues, impacts the acceptor substrate profiles of FucT III and FuvT V
E111D
-
site-directed mutagenesis of FucT-VI, the mutant activity is similar to the wild-type enzyme activity
I126V
-
site-directed mutagenesis of FucT-V, the mutant activity is similar to the wild-type enzyme activity
K73T
-
site-directed mutagenesis of FucT-VI, the mutant shows increased activity compared to the wild-type enzyme
K73T/E111D
-
site-directed mutagenesis of FucT-VI, the mutant shows increased activity compared to the wild-type enzyme
K73T/I75V/T87A
-
insertion mutagenesis of FucT-VI, the mutant shows altered substrate specificity compared to the wild-type enzyme
K73T/R110W
-
site-directed mutagenesis of FucT-VI, the mutant shows increased activity compared to the wild-type enzyme
K73T/R110W/E111D/V112I
-
site-directed mutagenesis of FucT-VI, the mutant shows increased activity compared to the wild-type enzyme
K97S
-
site-directed mutagenesis of FucT-VI, the mutant activity is similar to the wild-type enzyme activity
R110H
less than 10% of the wild type alpha-1,3-activity and undetectable alpha-1,4-activity
R110K
less than 10% of the wild type alpha-1,3-activity and undetectable alpha-1,4-activity
R110N
less than 10% of the wild type alpha-1,3-activity and undetectable alpha-1,4-activity
R110Q
R110W
R110W/E111D/V112I
-
site-directed mutagenesis of FucT-VI, the mutant shows increased activity compared to the wild-type enzyme
R96S
-
site-directed mutagenesis of FucT-VI, the mutant activity is similar to the wild-type enzyme activity
S110R
-
site-directed mutagenesis of FucT-V, the mutant activity is similar to the wild-type enzyme activity
S111K
-
site-directed mutagenesis of FucT-V, the mutant activity is similar to the wild-type enzyme activity
T87K
-
site-directed mutagenesis of FucT-V, the mutant shows decreased activity compared to the wild-type enzyme
T87K/D125E
-
site-directed mutagenesis of FucT-V, the mutant shows decreased activity compared to the wild-type enzyme
T87K/V89I/A101T
-
insertion mutagenesis of FucT-V, the mutant shows altered substrate specificity compared to the wild-type enzyme
T87K/W124R
-
site-directed mutagenesis of FucT-V, the mutant shows decreased activity compared to the wild-type enzyme
T87K/W124R/D125E/I126V
-
site-directed mutagenesis of FucT-V, the mutant shows decreased activity compared to the wild-type enzyme
V112I
-
site-directed mutagenesis of FucT-VI, the mutant activity is similar to the wild-type enzyme activity
W111A
alpha-1,4-activity is decreased to 10-20% of the wild type activity
W111F
alpha-1,4-activity is decreased to 42% of the wild type activity
W111R
-
the mutation changes the specificity for fucose transfer from H-type 1 to H-type 2 acceptors
W111Y
alpha-1,4-activity is decreased to 58% of the wild type activity
W11R/D112E
-
the mutation changes the specificity for fucose transfer from H-type 1 to H-type 2 acceptors. Increased type 2 activity compared to mutant W111R
W124A
alpha-1,4-activity is decreased to 20% of the wild type activity
W124F
alpha-1,4-activity is decreased to 17% of the wild type activity
W124R
W124R/D125E/I126V
-
site-directed mutagenesis of FucT-V, the mutant shows decreased activity compared to the wild-type enzyme
W124Y
alpha-1,4-activity is decreased to 52% of the wild type activity
additional information
-
construction of several chimeric mutants by domain swappig, overview
R110Q
less than 10% of the wild type alpha-1,3-activity and undetectable alpha-1,4-activity
R110Q
-
naturally occurring missense mutation in the FUT7 gene, the mutation abolishes FUT7 enzyme activity and synthesis of E-selectin binding ligands on leukocytes, and increases the expression of FUT4, the mutant shows unaltered synthesis of P-selectin binding ligand, overview
R110W
-
site-directed mutagenesis of FucT-VI, the mutant shows increased activity compared to the wild-type enzyme
W124R
-
site-directed mutagenesis of FucT-V, the mutant shows decreased activity compared to the wild-type enzyme
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
anion exchange-chromatography on a CM-Sepharose column, followed by an affinity chromatography on a GDP Fractogel column
-
native enzyme by preparation of microsome and Golgi membrane fractions, ultracentrifugation, and affinity chromatography
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
construction of plasmids encoding soluble forms of the recombinant human FucT-III where the human IL-2 sequence is linked to Ala47 or Val-36 of the FucT-III and expression in stable transfected BHK-21 cell lines
-
expression in Saccharomyces cerevisiae, construction of fusion genes PIR1-HA-FUT6 and PIR2-FLAG-FUT6
-
expression in Spodoptera frugiperda SF-9 cells, the secreted activity SFT3 increases until the 6th day of culture when it reaches the value 1.9 mU x 10e-6 cells and 13.4 mg/l, whereas only 5% of activity is retained inside the cells
-
expression of a secreted form of Fuc-TIII, SFT3, in two insect cell lines, Spodoptera frugiperda and Trichoplusia ni using the baculovirus expression system. The enzyme from the Tn cell line has a lower global charge, possibly due to post-translational modifications, such as phosphorylation or sulfation
-
expression of alpha-1,3/4-fucosyltransferase in the gastric pit cell lineage of FVB/N transgenic mice
-
plasmid ProtA-FucT-VI, encoding a soluble chimaeric protein consisting of a part of protein A fused to the catalytic domain of FucT-VI, transfected into Cos-7 cells
-
transient expression of cDNA splice variants FUT10-391, FUT10-419, and FUT10-479, and GFP-tagged-FUT10 cDNA constructs from vector PCR3.1 in COS-7 Cells
transient expression of cDNA splice variants FUT11-476 and FUT11-492 from vector PCR3.1 in COS-7 Cells
EXPRESSION
ORGANISM
UNIPROT
LITERATURE
FT3, FT6, and FT7 are markedly elevated in bone- and liver-metastatic prostate cancer and dictate synthesis of sialyl Lewis X and endothelial selectin ligands on metastatic prostate cancer cells
-
APPLICATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
molecular biology
-
the stable system using the expression vector pIB/Vf-His-TOPO constitutes an advance for the large scale expression of glycosyltransferases and possibly other glycoproteins in insect cells
synthesis
synthesis
-
the soluble form of fucosyltransferase III secreted by stably transfected cells may be used for in vitro synthesis of the Lewis 1 determinant on carbohydrates and glycoproteins
synthesis
-
by constructing yeast cells that display human FUT6 on the cell wall by fusion of FUT6 with the yeast cell wall proteins Pir1 and Pir2, the fucosylated oligosaccharides can be easily synthesized by the incubation of yeast cells with an appropriate donor and acceptor. It will thus be possible to prepare a large amount of immobilized FUT6 fused with Pir proteins in an inexpensive medium lacking the serum that is required for mammalian cell cultivation
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Wong, C.H.; Dumas, D.P.; Ichikawa, Y.; Koseki, K.; Danishefsky, S.J.; Weston, B.W.; Lowe, J.B.
Specificity, inhibition, and synthetic utility of a recombinant human alpha-1,3-fucosyltransferase
J. Am. Chem. Soc.
114
7321-7322
1992
Homo sapiens
-
Prieels, J.P.; Monnom, D.; Dolmans, M.; Beyer, T.A.; Hill, R.L.
Co-purification of the Lewis blood group N-acetylglucosaminide alpha 1-4 fucosyltransferase and an N-acetylglucosaminide alpha 1-3 fucosyltransferase from human milk
J. Biol. Chem.
256
10456-10463
1981
Homo sapiens
Palma, A.S.; Vila-Verde, C.; Pires, A.S.; Fevereiro, P.S.; Costa, J.
A novel plant alpha4-fucosyltransferase (Vaccinium myrtillus L.) synthesises the Lewisa adhesion determinant
FEBS Lett.
499
235-238
2001
Homo sapiens, Vaccinium myrtillus
Sousa, V.L.; Costa, M.T.; Palma, A.S.; Enguita, F.; Costa, J.
Localization, purification and specificity of the full-length membrane-bound form of human recombinant alpha 1,3/4-fucosyltransferase from BHK-21B cells
Biochem. J.
357
803-810
2001
Homo sapiens
Legault, D.J.; Kelly, R.J.; Natsuka, Y.; Lowe, J.B.
Human alpha(1,3/1,4)-fucosyltransferases discriminate between different oligosaccharide acceptor substrates through a discrete peptide fragment
J. Biol. Chem.
270
20987-20996
1995
Homo sapiens
Holmes, E.H.; Yen, T.Y.; Thomas, S.; Joshi, R.; Nguyen, A.; Long, T.; Gallet, F.; Maftah, A.; Julien, R.; Macher, B.A.
Human alpha1,3/4 fucosyltransferases. Characterization of highly conserved cysteine residues and N-linked glycosylation sites
J. Biol. Chem.
275
24237-24245
2000
Homo sapiens
Dupuy, F.; Germot, A.; Marenda, M.; Oriol, R.; Blancher, A.; Julien, R.; Maftah, A.
alpha1,4-Fucosyltransferase activity: a significant function in the primate lineage has appeared twice independently
Mol. Biol. Evol.
19
815-824
2002
Homo sapiens, Macaca mulatta
Morais, V.A.; Serpa, J.; Palma, A.S.; Costa, T.; Maranga, L.; Costa, J.
Expression and characterization of recombinant human alpha-3/4-fucosyltransferase III from Spodoptera frugiperda (Sf9) and Trichoplusia ni (Tn) cells using the baculovirus expression system
Biochem. J.
353
719-725
2001
Homo sapiens
Weston, B.W.; Nair, R.P.; Larsen, R.D.; Lowe, J.B.
Isolation of a novel human alpha (1,3)fucosyltransferase gene and molecular comparison to the human Lewis blood group alpha (1,3/1,4)fucosyltransferase gene. Syntenic, homologous, nonallelic genes encoding enzymes with distinct acceptor substrate specificities
J. Biol. Chem.
267
4152-4160
1992
Homo sapiens
Vo, L.; Lee, S.; Marcinko, M.C.; Holmes, E.H.; Macher, B.A.
Human alpha1,3/4-fucosyltransferases II. A single amino acid at the COOH terminus of FucT III and V alters their kinetic properties
J. Biol. Chem.
273
25250-25255
1998
Homo sapiens
Dupuy, F.; Petit, J.M.; Mollicone, R.; Oriol, R.; Julien, R.; Maftah, A.
A single amino acid in the hypervariable stem domain of vertebrate alpha1,3/1,4-fucosyltransferases determines the type 1/type 2 transfer. Characterization of acceptor substrate specificity of the Lewis enzyme by site-directed mutagenesis
J. Biol. Chem.
274
12257-12262
1999
Homo sapiens
Chandrasekaran, E.V.; Chawda, R.; Rhodes, J.M.; Xia, J.; Piskorz, C.; Matta, K.L.
Human lung adenocarcinoma alpha1,3/4-L-fucosyltransferase displays two molecular forms, high substrate affinity for clustered sialyl LacNAc type 1 units as well as mucin core 2 sialyl LacNAc type 2 unit and novel alpha1,2-L-fucosylating activity
Glycobiology
11
353-363
2001
Homo sapiens
Costa, J.; Grabenhorst, E.; Nimtz, M.; Conradt, H.S.
Stable expression of the Golgi form and secretory variants of human fucosyltransferase III from BHK-21 cells. Purification and characterization of an engineered truncated form from the culture medium
J. Biol. Chem.
272
11613-11621
1997
Homo sapiens
Kukowska-Latallo, J.F.; Larsen, R.D.; Nair, R.P.; Lowe, J.B.
A cloned human cDNA determines expression of mouse stage-specific embryonic antigen and the Lewis blood group alpha(1,3/1,4)fucosyltransferase
Genes Dev.
4
1288-1303
1990
Homo sapiens (P21217)
Cameron, H.S.; Szczepaniak, D.; Weston, B.W.
Expression of human chromosome 19p alpha(1,3)-fucosyltransferase genes in normal tissues. Alternative splicing, polyadenylation, and isoforms
J. Biol. Chem.
270
20112-20122
1995
Homo sapiens (P21217)
Elmgren, A.; Rydberg, L.; Larson, G.
Genotypic heterogeneity among Lewis negative individuals
Biochem. Biophys. Res. Commun.
196
515-520
1993
Homo sapiens (P21217)
Nishihara, S.; Yazawa, S.; Iwasaki, H.; Nakazato, M.; Kudo, T.; Ando, T.; Narimatsu, H.
alpha(1,3/1,4)fucosyltransferase (FucT-III) gene is inactivated by a single amino acid substitution in Lewis histo-blood type negative individuals
Biochem. Biophys. Res. Commun.
196
624-631
1993
Homo sapiens (P21217), Homo sapiens
Koda, Y.; Kimura, H.; Mekada, E.
Analysis of Lewis fucosyltransferase genes from the human gastric mucosa of Lewis-positive and -negative individuals
Blood
82
2915-2919
1993
Homo sapiens (P21217)
Mollicone, R.; Reguigne, I.; kelly, R.J.; Fletcher, A.; Watt, J.; Chatfield, S.; Aziz, A.; Cameron, H.S.; Weston, B.W.; Lowe, J.B.; Oriol, R.
Molecular basis for Lewis alpha(1,3/1,4)-fucosyltransferase gene deficiency (FUT3) found in Lewis-negative Indonesian pedigrees
J. Biol. Chem.
269
20987-20994
1994
Homo sapiens (P21217)
Nishihara, S.; Narimatsu, H.; Iwasaki, H.; Yazawa, S.; Akamatsu, S.; Ando, T.; Sena, T.; Narimatsu, I.
Molecular genetic analysis of the human Lewis histo-blood group system
J. Biol. Chem.
269
29271-29278
1994
Homo sapiens (P21217), Homo sapiens
Elmgren, A.; Boerjeson, C.; Svensson, L.; Rydberg, L.; Larson, G.
DNA sequencing and screening for point mutations in the human Lewis FUT gene enables molecular genotyping of the human Lewis blood group system
Vox Sang.
70
97-103
1996
Homo sapiens (P21217)
Elmgren, A.; Mollicone, R.; Costache, M.; Boerjeson, C.; Oriol, R.; Harrington, J.; Larson, G.
Significance of individual point mutations, T202C and C314T in the human Lewis FTA3' gene for expression of Lewis antigens by human alpha1,3/1,4'-fucosyltransferase, Fuc-TIII
J. Biol. Chem.
272
21994-21998
1997
Homo sapiens (P21217), Homo sapiens
Pang, H.; Liu, Y.; Koda, Y.; Soejima, M.; Jia, J.; Schlaphoff, T.; du Toit, E.D.; Kimura, H.
Five novel missense mutations of the Lewis gene FUT3' in African Xhosa and Caucasian populations in South Africa
Hum. Genet.
102
675-680
1998
Homo sapiens (P21217)
Koszdin, K.L.; Bowen, B.R.
The cloning and expression of a human alpha-1,3 fucosyltransferase capable of forming the E-selectin ligand
Biochem. Biophys. Res. Commun.
187
152-157
1992
Homo sapiens (P51993), Homo sapiens
Galan, M.C.; Venot, A.P.; Boons, G.J.
Glycosyltransferase activity can be modulated by small conformational changes of acceptor substrates
Biochemistry
42
8522-8529
2003
Homo sapiens
Niu, X.; Fan, X.; Sun, J.; Ting, P.; Narula, S.; Lundell, D.
Inhibition of fucosyltransferase VII by gallic acid and its derivatives
Arch. Biochem. Biophys.
425
51-57
2004
Homo sapiens (Q11130)
Stoykova, L.I.; Liu, A.; Scanlin, T.F.; Glick, M.C.
alpha1,3 Fucosyltransferases in cystic fibrosis airway epithelial cells
Biochimie
85
363-367
2003
Homo sapiens
Palma, A.S.; Morais, V.A.; Coelho, A.V.; Costa, J.
Effect of the manganese ion on human alpha3/4 fucosyltransferase III activity
BioMetals
17
35-43
2004
Homo sapiens
Norris, A.J.; Whitelegge, J.P.; Strouse, M.J.; Faull, K.F.; Toyokuni, T.
Inhibition kinetics of carba- and C-fucosyl analogues of GDP-fucose against fucosyltransferase V: implication for the reaction mechanism
Bioorg. Med. Chem. Lett.
14
571-573
2004
Homo sapiens
Chandrasekaran, E.V.; Chawda, R.; Rhodes, J.M.; Locke, R.D.; Piskorz, C.F.; Matta, K.L.
The binding characteristics and utilization of Aleuria aurantia, Lens culinaris and few other lectins in the elucidation of fucosyltransferase activities resembling cloned FT VI and apparently unique to colon cancer cells
Carbohydr. Res.
338
887-901
2003
Homo sapiens (P51993), Homo sapiens (Q11128)
Abe, H.; Ohba, M.; Shimma, Y.I.; Jigami, Y.
Yeast cells harboring human alpha-1,3-fucosyltransferase at the cell surface engineered using Pir, a cell wall-anchored protein
FEMS Yeast Res.
4
417-425
2004
Homo sapiens
Dupuy, F.; Germot, A.; Julien, R.; Maftah, A.
Structure/function study of Lewis alpha3- and alpha3/4-fucosyltransferases: the alpha1,4 fucosylation requires an aromatic residue in the acceptor-binding domain
Glycobiology
14
347-356
2004
Homo sapiens (P21217), Homo sapiens (P51993), Homo sapiens (Q11128), Hylobates lar (Q8HYJ3), Pongo pygmaeus (Q8HYJ4), Pongo pygmaeus (Q8HYJ5), Gorilla gorilla (Q8HYJ6), Gorilla gorilla (Q8HYJ7)
Morais, V.A.; Costa, J.
Stable expression of recombinant human alpha3/4 fucosyltransferase III in Spodoptera frugiperda Sf9 cells
J. Biotechnol.
106
69-75
2003
Homo sapiens
Guo, P.; Zhang, Y.; Zhang, X.Y.; Chen, H.L.; Wang, H.; Narimatsu, H.
Analysis of lewis antigens on cell surface and alpha1,3 fucosyltransferase subtypes in H7721 human hepatocarcinoma cells
J. Exp. Clin. Cancer Res.
22
135-139
2003
Homo sapiens
Bengtson, P.; Lundblad, A.; Larson, G.; Pahlsson, P.
Polymorphonuclear leukocytes from individuals carrying the G329A mutation in the alpha 1,3-fucosyltransferase VII gene (FUT7) roll on E- and P-selectins
J. Immunol.
169
3940-3946
2002
Homo sapiens
Dabrowska, A.; Baczynska, D.; Widerak, K.; Laskowska, A.; Ugorski, M.
Promoter analysis of the human alpha1,3/4-fucosyltransferase gene (FUT III)
Biochim. Biophys. Acta
1731
66-73
2005
Homo sapiens
Escrevente, C.; Machado, E.; Brito, C.; Reis, C.A.; Stoeck, A.; Runz, S.; Marme, A.; Altevogt, P.; Costa, J.
Different expression levels of alpha3/4 fucosyltransferases and Lewis determinants in ovarian carcinoma tissues and cell lines
Int. J. Oncol.
29
557-566
2006
Homo sapiens
Khaled, A.; Piotrowska, O.; Dominiak, K.; Auge, C.
Exploring specificity of glycosyltransferases: synthesis of new sugar nucleotide related molecules as putative donor substrates
Carbohydr. Res.
343
167-178
2008
Homo sapiens
Shetterly, S.; Jost, F.; Watson, S.R.; Knegtel, R.; Macher, B.A.; Holmes, E.H.
Site-specific fucosylation of sialylated polylactosamines by alpha1,3/4-fucosyltransferases-V and -VI is defined by amino acids near the N terminus of the catalytic domain
J. Biol. Chem.
282
24882-24892
2007
Homo sapiens
Lin, C.H.; Lin, C.W.; Khoo, K.H.
Proteomic identification of specific glycosyltransferases functionally implicated for the biosynthesis of a targeted glyco-epitope
Proteomics
8
475-483
2008
Homo sapiens (P21217), Homo sapiens (P51993)
Tefsen, B.; van Stijn, C.M.; van den Broek, M.; Kalay, H.; Knol, J.C.; Jimenez, C.R.; van Die, I.
Chemoenzymatic synthesis of multivalent neoglycoconjugates carrying the helminth glycan antigen LDNF
Carbohydr. Res.
344
1501-1507
2009
Homo sapiens
Fagerberg, D.; Angstroem, J.; Halim, A.; Hultberg, A.; Rakhimova, L.; Hammarstroem, L.; Boren, T.; Teneberg, S.
Novel Leb-like Helicobacter pylori-binding glycosphingolipid created by the expression of human alpha-1,3/4-fucosyltransferase in FVB/N mouse stomach
Glycobiology
19
182-191
2009
Homo sapiens
Carvalho, A.; Harduin-Lepers, A.; Magalhaes, A.; Machado, E.; Mendes, N.; Costa, L.; Matthiesen, R.; Almeida, R.; Costa, J.; Reis, C.
Differential expression of alpha-2,3-sialyltransferases and alpha-1,3/4-fucosyltransferases regulates the levels of sialyl Lewis a and sialyl Lewis x in gastrointestinal carcinoma cells
Int. J. Biochem. Cell Biol.
42
80-89
2010
Homo sapiens
Mollicone, R.; Moore, S.E.; Bovin, N.; Garcia-Rosasco, M.; Candelier, J.J.; Martinez-Duncker, I.; Oriol, R.
Activity, splice variants, conserved peptide motifs, and phylogeny of two new alpha1,3-fucosyltransferase families (FUT10 and FUT11)
J. Biol. Chem.
284
4723-4738
2009
Homo sapiens (Q495W5), Homo sapiens (Q6P4F1)
Barthel, S.; Wiese, G.; Cho, J.; Opperman, M.; Hays, D.; Siddiqui, J.; Pienta, K.; Furie, B.; Dimitroff, C.
Alpha 1,3 fucosyltransferases are master regulators of prostate cancer cell trafficking
Proc. Natl. Acad. Sci. USA
106
19491-19496
2009
Homo sapiens
Guo, Q.; Guo, B.; Wang, Y.; Wu, J.; Jiang, W.; Zhao, S.; Qiao, S.; Wu, Y.
Functional analysis of alpha1,3/4-fucosyltransferase VI in human hepatocellular carcinoma cells
Biochem. Biophys. Res. Commun.
417
311-317
2012
Homo sapiens
Seelhorst, K.; Piernitzki, T.; Lunau, N.; Meier, C.; Hahn, U.
Synthesis and analysis of potential alpha1,3-fucosyltransferase inhibitors
Bioorg. Med. Chem.
22
6430-6437
2014
Helicobacter pylori, Homo sapiens
Lunau, N.; Seelhorst, K.; Kahl, S.; Tscherch, K.; Stacke, C.; Rohn, S.; Thiem, J.; Hahn, U.; Meier, C.
Fluorescently labeled substrates for monitoring alpha1,3-fucosyltransferase IX activity
Chemistry
19
17379-17390
2013
Helicobacter pylori, Homo sapiens
Brazil, J.C.; Liu, R.; Sumagin, R.; Kolegraff, K.N.; Nusrat, A.; Cummings, R.D.; Parkos, C.A.; Louis, N.A.
alpha3/4 Fucosyltransferase 3-dependent synthesis of Sialyl Lewis A on CD44 variant containing exon 6 mediates polymorphonuclear leukocyte detachment from intestinal epithelium during transepithelial migration
J. Immunol.
191
4804-4817
2013
Homo sapiens
EXTERNAL LINKS (specific for EC-Number 2.4.1.65)
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
